<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Theriva Biologics, Inc. — News on 6ix</title>
<link>https://6ix.com/company/theriva-biologics-inc</link>
<description>Latest news and press releases for Theriva Biologics, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 17 Apr 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/theriva-biologics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d78c8a51cc36e4753450c6.webp</url>
<title>Theriva Biologics, Inc.</title>
<link>https://6ix.com/company/theriva-biologics-inc</link>
</image>
<item>
<title>Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting</title>
<link>https://6ix.com/company/theriva-biologics-inc/news/therivatm-biologics-announces-upcoming-presentation-of-additional-data-from-the-virage-phase-2b-clinical-trial-of-vcn-01-in-metastatic-pancreatic-cancer-at-aacr-2026-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/theriva-biologics-inc/news/therivatm-biologics-announces-upcoming-presentation-of-additional-data-from-the-virage-phase-2b-clinical-trial-of-vcn-01-in-metastatic-pancreatic-cancer-at-aacr-2026-annual-meeting</guid>
<pubDate>Fri, 17 Apr 2026 20:05:00 GMT</pubDate>
<description>- Tumor reponse, biomarker, and subgroup analyses from the VIRAGE Phase 2b clinical trial support a VCN-01 immune-mediated mode of action and demonstrate improved outcomes in VCN-01 treated patients across multiple subgroups, including patients with liver metastases - - Data to be presented in a poster session at the American Association of Cancer Research (AACR) Annual Meeting in San Diego, California on Monday April 20, 2026- ROCKVILLE, Md., April 17, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologic</description>
</item>
<item>
<title>Theriva™ Biologics Announces Positive End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma</title>
<link>https://6ix.com/company/theriva-biologics-inc/news/therivatm-biologics-announces-positive-end-of-phase-2-meeting-with-us-fda-regarding-the-design-of-a-phase-3-trial-of-vcn-01-in-metastatic-pancreatic-ductal-adenocarcinoma</link>
<guid isPermaLink="true">https://6ix.com/company/theriva-biologics-inc/news/therivatm-biologics-announces-positive-end-of-phase-2-meeting-with-us-fda-regarding-the-design-of-a-phase-3-trial-of-vcn-01-in-metastatic-pancreatic-ductal-adenocarcinoma</guid>
<pubDate>Mon, 23 Mar 2026 12:00:00 GMT</pubDate>
<description>– Successful meeting with FDA enables advancement into proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the first-line treatment of metastatic PDAC – – Combined feedback from FDA and previously from EMA enables company to finalize protocol for pivotal Phase 3 clinical trial while pursuing strategic funding opportunities ROCKVILLE, Md., March 23, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company deve</description>
</item>
<item>
<title>Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results</title>
<link>https://6ix.com/company/theriva-biologics-inc/news/therivatm-biologics-reports-full-year-2025-operational-highlights-and-financial-results-3</link>
<guid isPermaLink="true">https://6ix.com/company/theriva-biologics-inc/news/therivatm-biologics-reports-full-year-2025-operational-highlights-and-financial-results-3</guid>
<pubDate>Thu, 12 Mar 2026 12:00:00 GMT</pubDate>
<description>- Advancing clinical development of VCN-01 for pancreatic ductal adenocarcinoma and retinoblastoma - - Licensed SYN-020 to Rasayana Therapeutics for development in multiple indications; up to $38 million in potential milestones plus royalties on commercial sales - - Cash and cash equivalents of $13.1 million as of December 31, 2025; recent capital raises increase cash to $15.2 million as of February 26, 2026 and provides cash runway into Q1 2027- ROCKVILLE, M.D., March 12, 2026 (GLOBE NEWSWIRE)</description>
</item>
<item>
<title>Theriva™ Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications</title>
<link>https://6ix.com/company/theriva-biologics-inc/news/therivatm-biologics-licenses-syn-020-to-rasayana-therapeutics-for-multiple-indications</link>
<guid isPermaLink="true">https://6ix.com/company/theriva-biologics-inc/news/therivatm-biologics-licenses-syn-020-to-rasayana-therapeutics-for-multiple-indications</guid>
<pubDate>Wed, 18 Feb 2026 13:00:00 GMT</pubDate>
<description>- Theriva received a $300,000 upfront payment at signing and is eligible for up to $38M in development, regulatory, and sales milestones along with tiered single-digit royalties on net product sales - - Rasayana to assume all responsibility and costs for SYN-020 development and commercialization - ROCKVILLE, Md., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related disea</description>
</item>
<item>
<title>Theriva™ Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026</title>
<link>https://6ix.com/company/theriva-biologics-inc/news/therivatm-biologics-announces-upcoming-presentation-of-data-from-vcn-01-retinoblastoma-phase-1-clinical-trial-at-apao-2026</link>
<guid isPermaLink="true">https://6ix.com/company/theriva-biologics-inc/news/therivatm-biologics-announces-upcoming-presentation-of-data-from-vcn-01-retinoblastoma-phase-1-clinical-trial-at-apao-2026</guid>
<pubDate>Tue, 03 Feb 2026 13:00:00 GMT</pubDate>
<description>- Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in an invited session at the 41st Asia-Pacific Academy of Ophthalmology (APAO) Congress in Hong Kong on Saturday, 07 February 2026 – - Preclinical data will highlight synergistic antitumor activity for the combination of topotecan and VCN-01 that may improve outcomes in refractory retinoblastoma patients with difficult-to-treat vitreous seeds - ROCKVILLE, Md</description>
</item>
<item>
<title>Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)</title>
<link>https://6ix.com/company/theriva-biologics-inc/news/therivatm-biologics-announces-positive-scientific-advice-from-the-european-medicines-agency-ema-on-the-design-of-a-phase-3-trial-of-vcn-01-in-metastatic-pancreatic-ductal-adenocarcinoma-pdac</link>
<guid isPermaLink="true">https://6ix.com/company/theriva-biologics-inc/news/therivatm-biologics-announces-positive-scientific-advice-from-the-european-medicines-agency-ema-on-the-design-of-a-phase-3-trial-of-vcn-01-in-metastatic-pancreatic-ductal-adenocarcinoma-pdac</guid>
<pubDate>Mon, 29 Dec 2025 13:00:00 GMT</pubDate>
<description>- EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the first-line treatment of metastatic PDAC, including sample size, repeated dosing of VCN-01, and an adaptive design to potentially optimize trial timelines and outcomes - - Theriva to schedule an End-of-Phase 2 meeting with the FDA in H1 2026 to finalize the design of a pivotal multinational Phase 3 clinical trial - - Theriva’s cash runway until Q1 2027 support</description>
</item>
<item>
<title>Theriva™ Biologics Reports Third Quarter 2025 Operational Highlights and Financial Results</title>
<link>https://6ix.com/company/theriva-biologics-inc/news/therivatm-biologics-reports-third-quarter-2025-operational-highlights-and-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/theriva-biologics-inc/news/therivatm-biologics-reports-third-quarter-2025-operational-highlights-and-financial-results</guid>
<pubDate>Wed, 12 Nov 2025 13:00:00 GMT</pubDate>
<description>- Expanded data for VCN-01 (zabilugene almadenorepvec) in metastatic pancreatic ductal adenocarcinoma (PDAC) from the VIRAGE Phase 2b trial presented at the European Society for Medical Oncology (ESMO) Annual Congress 2025 - - Next generation oncolytic virus VCN-12 preclinical data presented at the 32nd Annual Congress European Society of Gene & Cell Therapy (ESGCT) - - Cash and cash equivalents of $7.5 millon as of September 30, 2025; recent capital raises increase cash to $15.5 million as of N</description>
</item>
<item>
<title>Theriva Biologics Provides Response to Unusual Market Action</title>
<link>https://6ix.com/company/theriva-biologics-inc/news/theriva-biologics-provides-response-to-unusual-market-action</link>
<guid isPermaLink="true">https://6ix.com/company/theriva-biologics-inc/news/theriva-biologics-provides-response-to-unusual-market-action</guid>
<pubDate>Fri, 24 Oct 2025 18:31:00 GMT</pubDate>
<description>ROCKVILLE, Md., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, announced today that the Company had become aware of unusual trading activity in its common stock on the NYSE American (the “NYSE”) on October 24, 2025. The Company is issuing this press release pursuant to Section 401(d) of the NYSE Company</description>
</item>
<item>
<title>Theriva™ Biologics Announces a Warrant Inducement Transaction for $4.0 Million in Gross Proceeds</title>
<link>https://6ix.com/company/theriva-biologics-inc/news/therivatm-biologics-announces-a-warrant-inducement-transaction-for-dollar40-million-in-gross-proceeds</link>
<guid isPermaLink="true">https://6ix.com/company/theriva-biologics-inc/news/therivatm-biologics-announces-a-warrant-inducement-transaction-for-dollar40-million-in-gross-proceeds</guid>
<pubDate>Thu, 16 Oct 2025 12:11:00 GMT</pubDate>
<description>ROCKVILLE, Md., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced its entry into a warrant inducement agreement with existing institutional investors of the Company for the immediate exercise of warrants to purchase up to 7,360,460 of common stock (the “Existing Warrants”) at a reduced exerc</description>
</item>
<item>
<title>Theriva™ Biologics Announces Upcoming Presentations at Medical Meetings</title>
<link>https://6ix.com/company/theriva-biologics-inc/news/therivatm-biologics-announces-upcoming-presentations-at-medical-meetings</link>
<guid isPermaLink="true">https://6ix.com/company/theriva-biologics-inc/news/therivatm-biologics-announces-upcoming-presentations-at-medical-meetings</guid>
<pubDate>Mon, 13 Oct 2025 12:00:00 GMT</pubDate>
<description>- VCN-01 expanded mPDAC data from VIRAGE Phase 2b trial to be presented at ESMO 2025 - - SYN-004 Interim blinded safety and pharmacokinetic data to be presented at IDWeek 2025 - Rockville, Md., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced upcoming presentations at the European Society f</description>
</item>
<item>
<title>Theriva™ Biologics Announces Presentation Describing Next Generation Oncolytic Adenovirus VCN-12 at the 32nd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)</title>
<link>https://6ix.com/company/theriva-biologics-inc/news/therivatm-biologics-announces-presentation-describing-next-generation-oncolytic-adenovirus-vcn-12-at-the-32nd-annual-congress-of-the-european-society-of-gene-and-cell-therapy-esgct</link>
<guid isPermaLink="true">https://6ix.com/company/theriva-biologics-inc/news/therivatm-biologics-announces-presentation-describing-next-generation-oncolytic-adenovirus-vcn-12-at-the-32nd-annual-congress-of-the-european-society-of-gene-and-cell-therapy-esgct</guid>
<pubDate>Mon, 06 Oct 2025 12:00:00 GMT</pubDate>
<description>- Preclinical data for VCN-12, the next candidate from Theriva’s VCN-X discovery program, highlight a novel mechanism of action with the potential to significantly improve antitumor effects - - Pre-ESGCT meeting monograph includes preclinical data demonstrating the feasibility of VCN-01 intracranial administration for the potential treatment of brain tumors - ROCKVILLE, Md., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified cl</description>
</item>
<item>
<title>Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results</title>
<link>https://6ix.com/company/theriva-biologics-inc/news/therivatm-biologics-reports-second-quarter-2025-operational-highlights-and-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/theriva-biologics-inc/news/therivatm-biologics-reports-second-quarter-2025-operational-highlights-and-financial-results</guid>
<pubDate>Mon, 11 Aug 2025 12:00:00 GMT</pubDate>
<description>- Released positive topline data from the VIRAGE Phase 2b study of VCN-01 (zabilugene almadenorepvec); expanded data to be presented at the European Society for Medical Oncology (ESMO) 2025 Congress in October - - VCN-01 demonstrates potential in retinoblastoma with Phase 1 safety and clinical outcome data presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting - - Cash and cash equivalents of $12.1 million as of June 30, 2025, expected cash runway into Q1 2026 - ROCKVI</description>
</item>
<item>
<title>Theriva™ Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at ASCO 2025 and Investigator Meeting to Review Topline Data from the VIRAGE Phase 2b Trial of VCN-01 in Metastatic Pancreatic Cancer</title>
<link>https://6ix.com/company/theriva-biologics-inc/news/therivatm-biologics-announces-presentation-of-data-from-vcn-01-retinoblastoma-phase-1-clinical-trial-at-asco-2025-and-investigator-meeting-to-review-topline-data-from-the-virage-phase-2b-trial-of-vcn-01-in-metastatic-pancreatic-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/theriva-biologics-inc/news/therivatm-biologics-announces-presentation-of-data-from-vcn-01-retinoblastoma-phase-1-clinical-trial-at-asco-2025-and-investigator-meeting-to-review-topline-data-from-the-virage-phase-2b-trial-of-vcn-01-in-metastatic-pancreatic-cancer</guid>
<pubDate>Tue, 27 May 2025 12:00:00 GMT</pubDate>
<description>- Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in a poster session at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on Saturday, May 31st, 2025 – - Theriva senior management to attend the ASCO conference and participate in an off-site investigator meeting to review the topline data from the VIRAGE Phase 2b clinical trial of VCN-01 in first-line metastatic pancreatic ductal ad</description>
</item>
<item>
<title>Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results</title>
<link>https://6ix.com/company/theriva-biologics-inc/news/therivatm-biologics-reports-first-quarter-2025-operational-highlights-and-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/theriva-biologics-inc/news/therivatm-biologics-reports-first-quarter-2025-operational-highlights-and-financial-results</guid>
<pubDate>Wed, 14 May 2025 12:40:00 GMT</pubDate>
<description>- VCN-01 Achieves Primary Efficacy and Safety Endpoints for Pancreatic Ductal Adenocarcinoma in VIRAGE Phase 2b Clinical Trial - - Closed a public offering on May 8, 2025, raising the Company’s cash balance and extending its cash runway into the first quarter of 2026 - ROCKVILLE, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, tod</description>
</item>
<item>
<title>Theriva Biologics Announces Closing of $7.5 Million Public Offering</title>
<link>https://6ix.com/company/theriva-biologics-inc/news/theriva-biologics-announces-closing-of-dollar75-million-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/theriva-biologics-inc/news/theriva-biologics-announces-closing-of-dollar75-million-public-offering</guid>
<pubDate>Thu, 08 May 2025 20:30:00 GMT</pubDate>
<description>ROCKVILLE, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the closing of its previously announced “reasonable best efforts” public offering of 6,818,180 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 6,818,180 shares of common stock at a</description>
</item>
<item>
<title>Theriva Biologics Announces Pricing of $7.5 Million Public Offering</title>
<link>https://6ix.com/company/theriva-biologics-inc/news/theriva-biologics-announces-pricing-of-dollar75-million-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/theriva-biologics-inc/news/theriva-biologics-announces-pricing-of-dollar75-million-public-offering</guid>
<pubDate>Wed, 07 May 2025 13:17:00 GMT</pubDate>
<description>ROCKVILLE, Md., May 07, 2025 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the pricing of its “reasonable best efforts” public offering for the purchase and sale of up to 6,818,180 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 6,818,180 shares of common</description>
</item>
<item>
<title>Theriva™ Biologics Announces Primary Endpoints for Efficacy and Safety Achieved in VIRAGE Phase 2b Clinical Trial of VCN-01 with Gemcitabine/nab-Paclitaxel in Newly-Diagnosed Metastatic Pancreatic Cancer Patients</title>
<link>https://6ix.com/company/theriva-biologics-inc/news/therivatm-biologics-announces-primary-endpoints-for-efficacy-and-safety-achieved-in-virage-phase-2b-clinical-trial-of-vcn-01-with-gemcitabinenab-paclitaxel-in-newly-diagnosed-metastatic-pancreatic-cancer-patients</link>
<guid isPermaLink="true">https://6ix.com/company/theriva-biologics-inc/news/therivatm-biologics-announces-primary-endpoints-for-efficacy-and-safety-achieved-in-virage-phase-2b-clinical-trial-of-vcn-01-with-gemcitabinenab-paclitaxel-in-newly-diagnosed-metastatic-pancreatic-cancer-patients</guid>
<pubDate>Wed, 07 May 2025 11:00:00 GMT</pubDate>
<description>- Patients treated with VCN-01 (zabilugene almadenorepvec) plus gemcitabine/nab-paclitaxel standard-of-care (SoC) chemotherapy had increased overall survival, progression free survival, and duration of response compared to patients treated with gemcitabine/nab-paclitaxel SoC - - VCN-01 was well-tolerated, with transient and reversible adverse events (AEs), meeting primary safety endpoint - - Greater differences between the treatment arms were observed in patients receiving 2 doses of VCN-01 - -</description>
</item>
</channel>
</rss>